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1. INTRODUCTION {#pace13670-sec-0040}
===============

Cardiac resynchronization therapy (CRT) is an established treatment for adult patients with heart failure (HF), impaired left ventricular (LV) function, and a wide QRS complex.[1](#pace13670-bib-0001){ref-type="ref"} Supporting evidence has emerged from numerous randomized, controlled trials and meta‐analyses thereof.[2](#pace13670-bib-0002){ref-type="ref"} Consequently, CRT is now widely accepted as a Class I indication (level of evidence A) for selected patients with nonischemic (NICM) or ischemic (ICM) cardiomyopathy.

It has been shown that CRT in adult congenital heart disease (ACHD) is feasible[3](#pace13670-bib-0003){ref-type="ref"}, [4](#pace13670-bib-0004){ref-type="ref"}; the Pediatric and Congenital Electrophysiology Society/Heart Rhythm Society (PACES/HRS) expert consensus statement on the recognition and management of arrhythmias in ACHD[5](#pace13670-bib-0005){ref-type="ref"} states that CRT is indicated in patients with ACHD with sinus rhythm, a systemic ventricular ejection fraction (SVEF) \<35%, left bundle branch block (LBBB), a QRS complex \>150 ms (spontaneous or paced), and a New York Heart Association (NYHA) class II to IV (ambulatory) symptoms. These indications, which are classified as a level of evidence "B," are based on presumed surrogate markers of clinical outcomes from adult populations with congenitally normal hearts, none of which have been validated against "hard endpoints" in ACHD. Moreover, no studies of CRT in the pediatric or ACHD population have involved randomization, and clinical outcome data are also lacking, even from observational studies.[5](#pace13670-bib-0005){ref-type="ref"} In addition, not all observational studies of CRT in ACHD have distinguished between structural ACHD (sACHD) and nonstructural ACHD, such as dilated cardiomyopathy and congenital complete heart block.[5](#pace13670-bib-0005){ref-type="ref"} In the absence of firm evidence in its favor, CRT in ACHD is not permitted in some countries, notably Japan.[6](#pace13670-bib-0006){ref-type="ref"}

In the context of the challenges in undertaking randomized, controlled studies in a young, heterogenous population with rare conditions, we sought to compare outcomes of CRT in adults with sACHD, NICM, or ICM.

2. METHODS {#pace13670-sec-0050}
==========

This is a retrospective study of patients with sACHD who had their first CRT device implantation at a tertiary referral center for ACHD (Queen Elizabeth Hospital, Birmingham, United Kingdom) from March 2002 to January 2017. Outcomes were compared with a population of adult patients with NICM or ICM who also underwent CRT device implantation in the same time period. Some adult patients with NICM or ICM have been included in previous publications.[7](#pace13670-bib-0007){ref-type="ref"} The study was approved by the Clinical Audit Department at the Queen Elizabeth Hospital, which permits publication of clinical data for the purposes of service evaluation. The study conforms with the Declaration of Helsinki.

The United Kingdom National Institute of Clinical Excellence (NICE) guidelines in 2007 recommended CRT‐pacing (CRT‐P) rather than CRT‐defibrillation (CRT‐D) for patients with NICM and indications for CRT. With a subsequent guideline change in 2014 recommending CRT‐D in NICM,[8](#pace13670-bib-0008){ref-type="ref"} the proportion of CRT‐D recipients increased thereafter. No specific guidelines have been issued by NICE or indeed any other guideline group as to the choice of CRT‐P or CRT‐D in the ACHD population. Consequently, device choice was dependent on physician\'s discretion.

2.1. Endpoints {#pace13670-sec-0060}
--------------

The primary endpoint was total mortality and the secondary endpoint was cardiac mortality, which included cardiac transplantation or implantation of a ventricular assist device. We also included the ancillary endpoint of unplanned HF hospitalization. Mortality data were collected through medical records and cross‐checked with a national mortality database. Clinical outcome data were collected every 6 months by investigators who were blinded to clinical and imaging data.

2.2. Device therapy {#pace13670-sec-0070}
-------------------

Device implantation was undertaken using standard transvenous techniques under general or local anesthesia and intravenous sedation, or via a thoracotomy with epicardial lead deployment under general anesthesia. The transvenous implantation technique in patients with sACHD varied according to the anatomy of the systemic ventricle and the location and accessibility of the coronary sinus and its tributaries. Implanters aimed at implanting the LV lead in a posterolateral vein. There was no systematic use of QLV interval, as evidence for this approach predated most of the implantations. The choice of CRT‐D and CRT‐P was based on the occurrence of sustained ventricular arrhythmias prior to implantation. After implantation, patients were followed‐up in dedicated device clinics. Up to 2013, patients in sinus rhythm underwent trans‐mitral Doppler‐directed optimization of atrioventricular delay using an iterative technique prior to discharge and at every scheduled visit. Routine echocardiographic optimization was abandoned thereafter and was only undertaken in symptomatic nonresponders. Backup atrial pacing was set at 60 beats/min, and the pacing mode was set to DDDR with an interventricular delay of 0‐20 ms (left ventricular \[LV\] first), according to clinician\'s discretion. In patients with permanent atrial fibrillation, systemic ventricular and nonsystemic ventricular leads were implanted and a CRT generator was used, plugging the atrial port and programming to a ventricular triggered mode, according to physician\'s choice. Atrioventricular junction ablation was undertaken according to physicians' decision. Patients underwent a clinical assessment on the day prior to implantation and at 1, 3, and every 6 months following device implantation.

### 2.2.1. Statistical analysis {#pace13670-sec-0080}

Continuous variables are expressed as mean (±standard deviation) and compared using the Student\'s *t*‐test. Categorical variables were compared using the chi‐squared statistic. Kaplan‐Meier curves and the log‐rank test were used to assess survival. Cox proportional hazard models were used to compare risks of the various endpoints. Proportionality hypotheses were verified by visual examination of log (survival) graphs to ensure parallel slopes, and by plotting Schoenfeld residuals. Statistical analyses were undertaken using Stata 14 (StataCorp, College Station, TX, USA). A two‐sided *P* ≤ .05 was considered statistically significant.

3. RESULTS {#pace13670-sec-0090}
==========

3.1. Baseline characteristics {#pace13670-sec-0100}
-----------------------------

The age distribution in the three study groups is shown in Figure [1](#pace13670-fig-0001){ref-type="fig"}. As shown in Table [1](#pace13670-tbl-0001){ref-type="table"}, patients with sACHD were mostly female (*P* \< .001). As expected, they were younger (*P* \< .001) and were less likely to have diabetes, hypertension, or a previous coronary artery bypass grafting. No differences emerged with respect to atrial rhythm, but left bundle branch block (LBBB) was less prevalent in the sACHD group (*P* \< .001). The sACHD group had a higher proportion of patients on *β*‐blockers (*P* = .002) but the groups were well matched for uptake of loop diuretics, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor antagonists (ARAs), and mineralocorticoid receptor antagonists. In the sACHD group, the SVEF was higher (*P* \< .001) and a greater proportion of patients underwent upgrades from pacemaker to CRT (*P* \< .001). The characteristics of individual patients and operation details are shown in Table [2](#pace13670-tbl-0002){ref-type="table"}.

![Age distribution according to etiology of cardiomyopathy. ACHD = adult congenital heart disease; ICM = ischemic cardiomyopathy; NICM = nonischemic cardiomyopathy \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](PACE-42-573-g001){#pace13670-fig-0001}

###### 

Characteristics of the study group

                               sACHD          ICM            NICM           *P*‐value
  ---------------------------- -------------- -------------- -------------- -----------
  N                            23             533            458            
  Sex (male), n (%)            13 (56.52)     425 (79.74)    294 (64.19)    \<.001
  Age (years)                  41.6 ± 13.5    74.4 ± 9.2     71.4 ± 11.9    \<.001
  NYHA class, n (%)                                                         
  I                            3 (13.64)      20 (3.88)      26 (5.96)      .304
  II                           3 (13.64)      68 (13.18)     68 (15.6)      
  III                          15 (68.18)     395 (76.55)    317 (72.71)    
  IV                           1 (4.55)       33 (6.4)       25 (5.73)      
  Device type, n (%)                                                        
  CRT‐D                        6 (26.09)      346 (64.92)    114 (24.89)    \<.001
  CRT‐P                        17 (73.91)     187 (35.08)    344 (75.11)    
  Upgrades from pacemaker      13 (56.5)      75 (14.07)     98 (21.40)     \<.001
  Comorbidity, n (%)                                                        
  Diabetes mellitus            2 (8.70)       162 (30.39)    88 (19.21)     \<.001
  Hypertension                 1 (4.35)       160 (30.02)    136 (29.69)    .029
  CABG                         --             148 (27.77)    32 (6.99)      \<.001
  ECG variables                                                             
  Sinus rhythm, n (%)          18 (78.26)     349 (65.48)    286 (62.45)    .228
  Atrial fibrillation, n (%)   5 (21.74)      184 (34.52)    172 (37.55)    
  LBBB, n (%)                  15 (65.22)     426 (79.92)    412 (89.96)    \<.001
  QRS duration (ms)            170.5 ± 30.8   152.8 ± 21.8   158.2 ± 21.8   \<.001
  Medication, n (%)                                                         
  Loop diuretics               22 (95.65)     513 (96.25)    431 (94.1)     .284
  ACEIs/ARAs                   21 (91.30)     459 (86.12)    391 (85.37)    .711
  *β*‐Blockers                 21 (91.30)     395 (74.11)    302 (65.94)    .002
  MRAs                         11 (47.83)     247 (46.34)    181 (39.52)    .088
  SVEF (%)                     32.8 ± 12.6    24.2 ± 9.3     25.1 ± 9.5     \<.001

*Note*. Variables are expressed as mean ± standard deviation, unless indicated otherwise.

Abbreviations: ACEIs = angiotensin‐converting enzyme inhibitors; ARAs = angiotensin receptor antagonists; CABG = coronary artery bypass grafting; CRT‐D = cardiac resynchronization therapy‐defibrillation; CRT‐P = cardiac resynchronization therapy‐pacing; ECG = electrocardiogram; ICM = ischemic cardiomyopathy; LBBB = left bundle branch block; MRAs = mineralocorticoid receptor antagonists; NICM = nonischemic cardiomyopathy; NYHA = New York Heart Association; sACHD = structural adult congenital heart disease; SVEF = systemic ventricular ejection function.

^a^Differences between the groups from analysis of variance for continuous variables and from chi‐squared tests for categorical variables.

^b^Permanent, persistent, and paroxysmal atrial fibrillation (AF).

John Wiley & Sons, Ltd.

###### 

Characteristics of individual adult congenital heart disease patients

  Patient number   Age (years)   Sex      Etiology                                Type of ventricle   Operations                                                                            Comorbidities                        Implantation approach   Device type   Implantation type
  ---------------- ------------- -------- --------------------------------------- ------------------- ------------------------------------------------------------------------------------- ------------------------------------ ----------------------- ------------- -------------------
  1                34            Male     Double outlet RV                        Single Ventricle    Fontan procedure                                                                      Myocardial infarction, LV thrombus   Transvenous             CRT‐P         De novo
  2                27            Female   Left atrial isomerism and AVSD          Systemic LV         AVSD repair, left AV valve repair                                                     None                                 Transvenous             CRT‐P         Upgrade
  3                55            Male     CCTGA                                   Systemic RV         TV replacement and MV replacement                                                     Diabetes mellitus, hypertension      Transvenous             CRT‐P         De novo
  4                29            Male     CCTGA                                   Systemic RV         Blalock‐Taussig shunt, VSD closure and RV‐PA conduit, redo RV‐PA conduit              Endocarditis                         Transvenous             CRT‐P         Upgrade
  5                47            Female   CCTGA with VSD and pulmonary stenosis   Systemic RV         None                                                                                  None                                 Transvenous             CRT‐P         Upgrade
  6                33            Female   VSD                                     Systemic LV         PA band, take‐down of PA band and VSD closure                                         Hepatorenal syndrome                 Transvenous             CRT‐P         De novo
  7                49            Male     VSD                                     Systemic LV         VSD repair                                                                            Anomalous coronary arteries          Transvenous             CRT‐P         Upgrade
  8                32            Male     CCTGA and VSD                           Systemic RV         LV‐PA conduit, VSD closure                                                            None                                 Transvenous             CRT‐P         Upgrade
  9                57            Female   ASD                                     Systemic LV         ASD closure                                                                           Rheumatoid arthritis, hypertension   Transvenous             CRT‐D         De novo
  10               28            Male     TGA with VSD and pulmonary stenosis     Systemic RV         Waterston shunt, Rastelli procedure, RV‐PA conduit                                    Hepatorenal syndrome                 Transvenous             CRT‐D         De novo
  11               19            Female   CCTGA                                   Systemic RV         PA band and take‐down of PA band                                                      None                                 Transvenous             CRT‐P         Upgrade
  12               36            Male     Pulmonary atresia and VSD               Systemic LV         Blalock‐Taussig shunt, RV‐PA conduit, AVR, aortic root and arch, redo RV‐PA conduit   None                                 Transvenous             CRT‐P         De novo
  13               50            Male     TOF                                     Systemic LV         TOF repair, PV replacement                                                            None                                 Transvenous             CRT‐D         Upgrade
  14               26            Female   CCTGA                                   Systemic RV         None                                                                                  None                                                         CRT‐P         Upgrade
  15               48            Female   ASD                                     Systemic LV         ASD closure, MV repair                                                                None                                 Transvenous             CRT‐P         Upgrade
  16               43            Female   Ebstein anomaly and ASD                 Systemic LV         ASD closure, TV replacement                                                           None                                 Surgical epicardial     CRT‐P         De novo
  17               33            Female   CCTGA                                   Systemic RV         Blalock‐Taussig shunt, VSD closure, pulmonary valvotomy, MV repair, PV replacement    None                                 Surgical epicardial     CRT‐P         Upgrade
  18               54            Female   VSD                                     Systemic LV         VSD repair                                                                            None                                 Transvenous             CRT‐D         De novo
  19               28            Male     Double outlet RV                        Single Ventricle    Cavopulmonary shunt, Fontan procedure                                                 None                                 Surgical epicardial     CRT‐P         Upgrade
  20               59            Male     TOF                                     Systemic LV         Blalock‐Taussig shunt, TOF repair, PV replacement                                     Membranous nephropathy               Transvenous             CRT‐P         Upgrade
  21               40            Male     AVSD                                    Systemic LV         Left AVSD repair, left AV valve replacement                                           None                                 Transvenous             CRT‐P         Upgrade
  22               60            Male     TOF                                     Systemic LV         TOF repair, PV replacement                                                            None                                 Transvenous             CRT‐D         De novo
  23               69            Male     CCTGA                                   Systemic RV         None                                                                                  Myocardial infarction                Transvenous             CRT‐D         De novo

Abbreviations: ASD = atrial septal defect; AV = atrioventricular; AVSD = atrioventricular septal defect; CCTGA = congenitally corrected transposition of the great arteries; CRT‐D = cardiac resynchronization therapy‐defibrillation; CRT‐P = cardiac resynchronization therapy‐pacing; LV = left ventricle; MV, mitral valve; PA = pulmonary artery; PV = pulmonary valve; TGA = transposition of the great arteries; TOF = tetralogy of Fallot; RV = right ventricle; TV = tricuspid valve; VSD = ventricular septal defect.

John Wiley & Sons, Ltd.

3.2. Outcomes {#pace13670-sec-0110}
-------------

Over 4.1 years (median 4.1 years; interquartile range: 2.2‐6.1 years), total mortality was 5/23 (21.7%; 4.4 per 100 person‐years) in the sACHD group, 221/533 (41.5%; 11.8 per 100 person‐years) in the ICM group, and 154/458 (33.6%; 9.7 per 100 person‐years) in the NICM group (Table [3](#pace13670-tbl-0003){ref-type="table"}). There were two patients who underwent implantations of a LV assist device, one in the ICM group and one in the NICM group. None underwent cardiac transplantation. Kaplan‐Meier survival analyses are shown in Figure [2](#pace13670-fig-0002){ref-type="fig"}. In univariate Cox proportional hazards models, total mortality in sACHD was lower than in ICM (hazard ratio \[HR\]: 0.38; 95% confidence interval \[CI\] 0.15‐0.91), but similar to NICM (HR: 0.48, 95% CI 0.20‐1.16). Cardiac mortality in sACHD was similar to ICM (HR: 0.78, 95% CI 0.32‐1.92) and NICM (HR: 1.12, 95% CI 0.45‐2.78). Similarly, HF hospitalization was similar to ICM (HR: 0.44, 95% CI 0.11‐1.77) and NICM (HR: 0.75, 95% CI 0.18‐3.08). Age, sex, NYHA class, diabetes, atrial rhythm, QRS duration, LVEF, and treatment with loop diuretics, ACEIs/ARAs, and *β*‐blockers also emerged as significant predictors of total mortality (Online Appendix) and these variables were included in multivariate analyses. Multivariate analyses showed no differences in total mortality, cardiac mortality, or HF hospitalization between sACHD and ICM or NICM (Table [4](#pace13670-tbl-0004){ref-type="table"}).

###### 

Univariate analyses

                       Events                  
  -------------------- ---------- ------------ ------------
  Total mortality      5 (21.7)   221 (41.5)   154 (33.6)
  Cardiac mortality    5 (21.7)   106 (19.9)   67 (14.6)
  HF hospitalization   2 (8.69)   84 (15.8)    45 (9.82)

*Note*. Results are expressed in terms of absolute number and percentage of events. ACHD = adult congenital heart disease; HF = heart failure; ICM = ischemic cardiomyopathy; NICM = nonischemic cardiomyopathy.

John Wiley & Sons, Ltd.

![Clinical outcomes after cardiac resynchronization therapy according to etiology of cardiomyopathy. ACHD = adult congenital heart disease; ICM = ischemic cardiomyopathy; NICM = nonischemic cardiomyopathy \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](PACE-42-573-g002){#pace13670-fig-0002}

###### 

Univariate and multivariate analyses

                          sACHD vs ICM   sACHD vs NICM                                       
  ----------------------- -------------- --------------- ------ ------- ------ ------ ------ -------
  Univariate analyses                                                                        
  Total mortality         0.38           0.15            0.91   0.031   0.48   0.20   1.16   0.103
  Cardiac mortality       0.78           0.32            1.92   0.592   1.12   0.45   2.78   0.809
  HF hospitalization      0.44           0.11            1.77   0.247   0.75   0.18   3.08   0.685
  Multivariate analyses                                                                      
  Total mortality         1.27           0.42            3.79   0.674   2.66   0.75   9.41   0.128
  Cardiac mortality       3.19           0.98            10.4   0.054   2.65   0.66   10.6   0.168
  HF hospitalization      1.51           0.29            7.88   0.625   1.95   0.38   10.0   0.422

*Notes*. Comparison of events in patients with sACHD, using ICM and NICM as reference. Results are expressed in terms of hazard ratios and 95% confidence intervals. In multivariate analyses, there was covarite adjustment for age, sex, New York Heart Association class, diabetes, atrial rhythm, QRS duration, left ventricular ejection fraction, and treatment with loop diuretics, angiotensin‐converting enzyme inhibitors/angiotensin receptor antagonists, and *β*‐blockers as covariates (see Online Appendix).

Abbreviation: HF = heart failure; ICM = ischemic cardiomyopathy; NICM = nonischemic cardiomyopathy; sACHD = structural adult congenital heart disease.

John Wiley & Sons, Ltd.

4. DISCUSSION {#pace13670-sec-0120}
=============

This is the first study to address long‐term outcomes of CRT in patients with ACHD.[5](#pace13670-bib-0005){ref-type="ref"} We found that after CRT, total mortality, cardiac mortality, and HF hospitalization in sACHD were similar to adults with ICM or NICM, after adjustment for potential confounders.

Although CRT is being undertaken in the pediatric and adult population with sACHD, studies in its favor have only focused on surrogate predictors of outcome. In a study of 20 patients, Sakaguchi et al showed that in a mixed population of children and adult patients with a systemic LV or single ventricular physiology, CRT led to a reduction in ventricular volume.[9](#pace13670-bib-0009){ref-type="ref"} In a retrospective study comprising children with CHD (n = 73) or cardiomyopathy (n = 16) (median age 12.8 years; follow‐up of 4 months), the SVEF improved after CRT.[4](#pace13670-bib-0004){ref-type="ref"} In a retrospective study of 60 children and adults with CHD aged between 5 months and 47 years, which included 46 patients with ACHD and 14 patients with dilated cardiomyopathy (mean age 15 years), CRT was associated with an increase in SVEF from 36% to 42% (*P* \< .001) and an improvement in functional status was observed in 87% of patients with follow‐up data.[10](#pace13670-bib-0010){ref-type="ref"} Merchant et al also found that in adult patients with repaired tetralogy of Fallot, improvements in LVEF were sustained after 53.4 months.[11](#pace13670-bib-0011){ref-type="ref"} In a recent retrospective study including 48 patients with ACHD (median age: 47 years) followed‐up over a median of 2.6 years, 77% responded to CRT either by improvement of NYHA functional class and/or systemic ventricular function.[3](#pace13670-bib-0003){ref-type="ref"} These data, which are based on surrogate outcome measures, are consistent with our findings that outcomes of CRT in sACHD are similar to adult patients with NICM or ICM.

In this study, more than half of patients with sACHD were upgraded from pacemakers to CRT. This is not unexpected, as both sACHD and operations for sACHD lead to conduction system disturbances. Although we do not have access to the SVEF prior to pacemaker implantation, the SVEF at the time of upgrade was severely impaired. This could be due to the natural progression of CHD, but we cannot discount the possibility that subpulmonary ventricular pacing may have contributed to a deterioration in systemic ventricular function. In this respect, right ventricular (RV) pacing is associated with impairment of LV function and a risk of HF in adult patients with NICM or ICM.[12](#pace13670-bib-0012){ref-type="ref"}, [13](#pace13670-bib-0013){ref-type="ref"}, [14](#pace13670-bib-0014){ref-type="ref"}, [15](#pace13670-bib-0015){ref-type="ref"} In patients with sick sinus syndrome, up to 40% develop HF with RV pacing.[16](#pace13670-bib-0016){ref-type="ref"}, [17](#pace13670-bib-0017){ref-type="ref"} In the Dual Chamber and VVI Implantable Defibrillator (DAVID) study[12](#pace13670-bib-0012){ref-type="ref"}, [18](#pace13670-bib-0018){ref-type="ref"} and the Mode Selection Trial (MOST),[13](#pace13670-bib-0013){ref-type="ref"} RV pacing was also associated with a higher risk of HF hospitalization. In patients with CHD, Moak et al showed an improvement in clinical status after upgrading from pacemakers to CRT in six patients aged 11.3 years with NICM.[19](#pace13670-bib-0019){ref-type="ref"} No data are available in patients with sACHD. Unfortunately, our sample is also too small to explore the effects of upgrading to CRT in sACHD. It would appear, however, that the long‐term outcome of CRT in patients with sACHD is comparable to adult patients with NICM, despite the fact that more than half of patients were upgraded from pacemakers. Whether or not pacing the systemic ventricle in patients with sACHD and conventional indications for pacing is preferable to pacing the nonsystemic ventricle remains unexplored.

In this study, patient selection for CRT was driven by the presence of HF symptoms, a wide QRS complex (intrinsic or paced) and impaired SV function, in the background of maximum tolerated medical therapy. Importantly, there will be a selection bias, which was not addressed, insofar as some sACHD patients would not have undergone CRT because of problems with access to peripheral or coronary sinus veins. Physician preference therefore played a role in patient selection.

4.1. Limitations {#pace13670-sec-0130}
----------------

The small sample size is the main limitation of this study. Given the trends observed herein, larger numbers could show that CRT is better in ACHD after CRT compared to non‐ACHD. Clearly, a congenitally abnormal heart is not the same as a structural normal heart with acquired disease. By definition, age is an inescapable covariate of ACHD. Although we have included age in statistical analyses, the biological interaction between age and ACHD cannot be corrected for by statistical means. Caution is therefore appropriate when interpreting the results of these analyses. Unfortunately, follow‐up echocardiograms were not systematically collected and therefore, we are unable to comment on the effects of CRT on LV reverse remodeling. Last, we do not have control groups that were not treated with CRT and therefore, we cannot comment on the relative benefit of CRT, but only on the possible effects of the underlying "substrate."

5. CONCLUSIONS {#pace13670-sec-0140}
==============

We found that after CRT, total mortality, cardiac mortality, or HF hospitalization in sACHD was similar to patients with ICM or NICM. Our findings have emerged in the context that observational studies in the sACHD have not addressed long‐term outcomes in patients with sACHD and that a randomized controlled trial of CRT in this patient population is unlikely to emerge.
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